Literature DB >> 31069988

Laboratory diagnosis of heparin-induced thrombocytopenia.

Theodore E Warkentin1,2,3,4.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a clinical-pathological disorder; thus, laboratory testing for the pathogenic platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies is central for diagnosis. The "iceberg" model summarizes the inter-relationship between platelet activation assays and PF4-dependent immunoassays, with platelet-activating antibodies comprising a subset of anti-PF4/heparin antibodies. The platelet serotonin-release assay (SRA), performed by reference laboratories, has high sensitivity and specificity for HIT (~95% each), and is especially suited for detecting highly pathogenic HIT sera containing both heparin-dependent and heparin-independent platelet-activating antibodies; this latter subgroup of antibodies explains "autoimmune HIT" disorders (delayed-onset, persisting, spontaneous, heparin "flush," fondaparinux-associated). Recently, SRA-negative HIT has become recognized, in which serum from some HIT patients contains subthreshold levels of platelet-activating antibodies (by SRA) that become detectable using a PF4-enhanced platelet activation assay. Unusual immunologic features of HIT include early antibody detectability (at onset of platelet count fall) and antibody transience (seroreversion). Widely available PF4-dependent enzyme immunoassays (EIAs) have high sensitivity but poor specificity for HIT, although specificity is enhanced with IgG-specific EIAs and strong positive results; unfortunately, EIA results are usually not available in real time. Automated rapid immunoassays, such as the chemiluminescence immunoassay (CLIA) and latex immunoturbidimetric assay (LIA), facilitate real-time laboratory diagnosis. Recently available likelihood ratio (LR) data for positive (LR+) and negative (LR-) test results allow clinicians to adjust their pretest probabilities for HIT, using Bayesian analysis, into real-time posttest probabilities that are dramatically increased (test positive) or decreased (test negative). Moreover, (semi-)quantitative CLIA- and LIA-positive results (weak, moderate, strong positive) can further refine the posttest probability of HIT.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  (autoimmune) heparin-induced thrombocytopenia; Bayesian analysis; chemiluminescence immunoassay; latex immunoturbidimetric assay; rapid immunoassays; serotonin-release assay

Mesh:

Substances:

Year:  2019        PMID: 31069988     DOI: 10.1111/ijlh.12993

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  20 in total

1.  Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience.

Authors:  Francesca Cesari; Silvia Sorrentino; Anna Maria Gori; Angela Rogolino; Raimondo De Cristofaro; Betti Giusti; Elena Sticchi; Erica De Candia; Rossella Marcucci
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

2.  Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.

Authors:  Adam J Kanack; Antonios Bayas; Gemlyn George; Mouhamed Yazan Abou-Ismail; Bandana Singh; Mindy C Kohlhagen; Noah P Splinter; Monika Christ; Markus Naumann; Karen A Moser; Kristi J Smock; Alison Grazioli; Renren Wen; Demin Wang; David L Murray; Anand Padmanabhan
Journal:  Blood       Date:  2022-07-07       Impact factor: 25.476

3.  SARS-CoV-2 and pulmonary embolism: who stole the platelets?

Authors:  Michael Tran; Chirag Sheth; Rohan Bhandari; Scott J Cameron; Deborah Hornacek
Journal:  Thromb J       Date:  2020-09-03

4.  A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.

Authors:  Stefan Handtke; Martina Wolff; Carlo Zaninetti; Jan Wesche; Linda Schönborn; Konstanze Aurich; Lena Ulm; Nils-Olaf Hübner; Karsten Becker; Thomas Thiele; Andreas Greinacher
Journal:  Blood       Date:  2021-07-01       Impact factor: 25.476

5.  Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

Authors:  Jonathan Douxfils; Julien Favresse; Jean-Michel Dogné; Thomas Lecompte; Sophie Susen; Charlotte Cordonnier; Aurélien Lebreton; Robert Gosselin; Pierre Sié; Gilles Pernod; Yves Gruel; Philippe Nguyen; Caroline Vayne; François Mullier
Journal:  Thromb Res       Date:  2021-05-15       Impact factor: 3.944

6.  Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT).

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; James W Smith; Na Li; Jane C Moore; Donald M Arnold; Ishac Nazy
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

Review 7.  Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Authors:  Brigitte Tardy; Thomas Lecompte; François Mullier; Caroline Vayne; Claire Pouplard
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

8.  Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic.

Authors:  Mayte Sánchez van Kammen; Mirjam R Heldner; Justine Brodard; Adrian Scutelnic; Suzanne Silvis; Verena Schroeder; Johanna A Kremer Hovinga; Saskia Middeldorp; Marcel Levi; Sini Hiltunen; Erik Lindgren; Maryam Mansour; Antonio Arauz; Miguel A Barboza; Susanna M Zuurbier; Diana Aguiar de Sousa; Jose M Ferro; Urs Fischer; Thalia S Field; Katarina Jood; Turgut Tatlisumak; Jukka Putaala; Marcel Arnold; Jonathan M Coutinho
Journal:  JAMA       Date:  2021-07-27       Impact factor: 56.272

9.  A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.

Authors:  Bethany Samuelson Bannow; Deepti M Warad; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Ruchika Sharma; Diane E Grill; Mary W Redman; Parisa R Khalighi; Rachel R Leger; Rajiv K Pruthi; Dong Chen; Daniel E Sabath; Richard H Aster; David A Garcia; Anand Padmanabhan
Journal:  Blood       Date:  2021-02-25       Impact factor: 25.476

Review 10.  Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies.

Authors:  Theodore E Warkentin
Journal:  Hamostaseologie       Date:  2020-10-22       Impact factor: 1.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.